How Novo Nordisk Will Protect Insulin Sales

Nearly 1 in 5 Americans with diabetes require some form of insulin, and out-of-pocket expenses for the life-sustaining medicine have doubled over the past 10 years. As the global leader in the insulin market, pharmaceutical giant Novo Nordisk (NYSE: NVO) must maintain revenue in the face of calls to lower treatment costs -- but one new development on the horizon may offer its future sales a partial reprieve. Scientists developing new drug treatmentThe White House has been promising lower prescription drug prices for several years. President Biden discussed capping insulin prices at $35 a month, and the House followed suit by passing the Affordable Insulin Now Act at the end of March. Opponents point out that much of the difference between out-of-pocket and drug expenses will be picked up by the government, so the act will do little to bring down the high insulin costs charged by drugmakers.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"